This site is intended for healthcare professionals
  • Home
  • /
  • Clinical trials
  • /
  • Cancer-Associated Thrombosis
  • /
  • Rivaroxaban in the Treatment of Venous Thromboembo...
Clinical trial

Rivaroxaban in the Treatment of Venous Thromboembolism (VTE) in Cancer Patients

Read time: 1 mins
Last updated:17th Apr 2019
Status: Recruiting
Identifier: NCT02583191
Rivaroxaban in the Treatment of Venous Thromboembolism (VTE) in Cancer Patients


Brief Summary:

The purpose of this study is to show feasibility (efficacy and safety) of Rivaroxaban in the treatment of VTE in cancer patients in comparison to the standard treatment with low molecular weight heparin (LMWH).

Tumor patients with active cancer and newly diagnosed thromboembolic events are randomised to receive either Rivaroxaban or the standard treatment with low-molecular heparin.


Study Type: Interventional (Clinical Trial)
Estimated Enrollment: 450 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: CONKO_011/ AIO-SUP-0115/Ass.: Rivaroxaban in the Treatment of Venous Thromboembolism (VTE) in Cancer Patients - a Randomized Phase III Study
Study Start Date: March 2016
Estimated Primary Completion Date: December 2019
Estimated Study Completion Date: December 2019

Arms:
- Experimental: Rivaroxaban
- Active Comparator: low-molecular heparine

Category Value
Study type(s) Interventional
Expected enrolment 450
Study start date 01 March 2016
Actual study completion date 01 December 2019

View full details